We report a case series of buprenorphine-related respiratory and neurological depression in opioid-naïve elderly hospitalised patients who received buprenorphine for acute pain management at our institution over a 24-month period. All six patients had risk factors for respiratory depression such as advanced age, concurrent comorbidities, or the ingestion of other potential central nervous system depressants. All patients required escalation of management with additional monitoring, with some transferred to a high dependency or intensive care unit. Five patients had attempted naloxone reversal with varying results. Our cases highlight the fact that while buprenorphine has been demonstrated to have a ceiling effect in relation to respiratory depression in healthy volunteers, it remains an important side-effect and may result in significant respiratory depression in patients with reduced respiratory or neurological reserve. Difficulties with buprenorphine's reversal using naloxone are described. We recommend additional caution when considering buprenorphine for acute pain management in elderly opioid-naïve patients, especially if they have comorbidities or are taking other central nervous system depressants. When buprenorphine is used in patients with risk factors, we recommend additional monitoring and education about potential adverse respiratory effects and their management.
Introduction
Buprenorphine is a unique semisynthetic opioid with favourable characteristics used extensively for analgesia in both cancer and non-cancer pain [1] [2] [3] [4] [5] . In particular, its ceiling for respiratory depression but not of its analgesic effect has been well documented 5, 6 . The presumption of limited respiratory depression has contributed to its widespread use for the management of acute pain in our hospital. However, we have recently observed several cases of buprenorphineassociated respiratory depression amongst elderly patients. This was surprising given the prevalent thought about the absence of significant respiratory depression in patients receiving buprenorphine. Moreover, these patients required significant changes in their management, including for some, transfer to higher levels of care and additional organ support to prevent serious morbidity. An apparent lack of efficacy with routine naloxone administration was also observed. Given these initial anecdotal observations we undertook a retrospective review of all cases of buprenorphine-related respiratory depression that required an escalation of management in our hospital over a 24-month period. The aim was to estimate the incidence of respiratory depression in our patients receiving buprenorphine for acute pain, and to assess whether there were any clinical features that were common amongst these patients. This required a detailed review of each case. For this reason, a brief case history of each patient is presented.
Methods
After institutional Human Research Ethics Committee approval (10199), all patients from September 2013 through to September 2015 who suffered clinically significant buprenorphine toxicity at the Sir Charles Gairdner Hospital (SCGH) were identified from our intensive care unit (ICU) and high dependency unit (HDU) databases or from our acute pain service (APS) database.
SCGH is a tertiary academic hospital in Perth, Western Australia. The intensive care and high dependency units admit approximately 1,500 and 800 patients respectively on an annual basis. Both medical and surgical patients are admitted to these units, with the HDU managing patients requiring lower levels of organ support and monitoring, including non-invasive ventilatory support and low-dose vasopressor support. Opioid toxicity complicating acute pain management in a hospitalised patient results in approximately three admissions to the HDU and ICU per year.
Our acute pain service manages about 2,900 new patients per year. This is on a referral basis and includes a mixture of both medical and surgical patients. Buprenorphine is typically used for breakthrough pain relief in the majority of these patients. Buprenorphine may also be prescribed by other practitioners outside our acute pain service. Patients admitted to ICU or HDU with a primary or secondary diagnosis of opioid toxicity were identified using the SCGH clinical coding patient database. Other patients with documented buprenorphine-associated adverse events requiring escalation of management but not necessitating high acuity care were identified from our APS audit database. Retrospective medical record and electronic database review was conducted. Patients were included if buprenorphine was temporally related to clinically significant respiratory and neurological deterioration. Presenting conditions, concurrent medications, alterations in respiratory and neurological state, haemodynamic parameters, use of a reversal agent, laboratory investigations and clinical course were reviewed.
Written consent was obtained from all patients or if necessary, their next-of-kin, for publication of their details.
Case histories

Case 1
An 85-year-old woman, who lived independently with her husband, was admitted for elective repair of an infrarenal abdominal aortic aneurysm. She underwent an uncomplicated endovascular aortic repair, utilising total intravenous anaesthesia with remifentanil and propofol. Fentanyl 50 μg was given 30 minutes prior to completion of the procedure. In the post anaesthesia care unit (PACU) her Glasgow Coma Scale (GCS) score was 15, respiratory rate 12-23 /minute and oxygen saturations consistently 99% with oxygen 6 litres/minute via Hudson mask.
An arterial blood gas at the end of the recovery period (approximately three hours post procedure) showed PaCO 2 41 mmHg, PaO 2 161 mmHg, pH 7.39 and HCO 3 -24 mmol/l. Blood glucose was normal. Buprenorphine 200 μg was given sublingually for analgesia prior to leaving the PACU.
A progressive drop in her GCS was noted by the team over the next few hours despite receiving no other medications with the potential to cause neurological or respiratory depression. Approximately six hours after returning to the ward her GCS was 9. Her respiratory rate was 9 /minute, with other haemodynamic parameters being normal. Her arterial blood gas showed pH 7.06, PaCO 2 106 mmHg, PaO 2 180 mmHg, and HCO 3 -28 mmol/l. Blood glucose and serum electrolytes were normal. Her brain computed tomography scan showed absence of acute intracranial pathology. She was admitted to the HDU and non-invasive ventilation (NIV) was initiated. Naloxone 1.2 mg was given as an intravenous (IV) bolus dose, with little immediate improvement in respiratory or neurological parameters. She gradually improved over the course of the night, with a return to a normal conscious state and cessation of NIV the following morning. Her PaCO 2 at this time was 42 mmHg, 16 hours after sublingual buprenorphine administration. She was discharged from the HDU. Buprenorphine was avoided for the remainder of her stay. Her recovery was otherwise unremarkable and she was discharged from hospital a day later.
Case 2
A 92-year-old woman was admitted to hospital after a fall resulting in a left-sided rib fracture. She did not sustain any head trauma. Prior to admission, she lived at home, managing functional activities with the assistance of her daughter.
On admission, her vital signs and conscious state were normal. She was initially given paracetamol and codeine phosphate combination 1 g/60 mg and ibuprofen 200 mg for pain relief. Her observations remained normal over the next five hours. Buprenorphine 200 μg was given sublingually at five and then again at eight hours after admission for breakthrough pain. Two hours after the second buprenorphine dose was administered, her arterial blood gas showed a respiratory acidosis, with pH 7.17, PaCO 2 69 mmHg, HCO 3 -24 mmol/l and PaO 2 77 mmHg. Blood glucose and serum electrolytes were normal, besides a mildly elevated ionised calcium of 1.7 mmol/l in the context of known hyperparathyroidism. A progressive deterioration in her level of consciousness was noted over the following hours, resulting in a GCS of 9, six hours after the last buprenorphine dose. This occurred despite the administration of naloxone 1 mg given in divided doses during this period. She was admitted to HDU and a naloxone infusion was initiated at 600 μg/hour. The infusion was continued for 20 hours. During this time, her GCS fluctuated between 12 and 15. Alternative pain strategies were introduced including a paravertebral block with a 0.2% ropivacaine infusion running at 10 ml/hour.
Increasing oxygen requirements, consistent with aspiration pneumonia were noted. Further deterioration led to reassessment of her situation with her family and a shift in care towards comfort measures with input from the palliative care team. She died four days after hospital admission.
Case 3
A 78-year-old woman underwent an elective right total knee replacement. Intrathecal ropivacaine was used in conjunction with femoral and sciatic nerve catheters. Buprenorphine 300 μg was administered via the femoral nerve catheter together with 20 ml of 0.375% ropivacaine. Ropivacaine together with clonidine 150 μg was administered in the sciatic nerve catheter. A low-dose propofol infusion was used for light sedation at the beginning of the case. No other opioids were administered throughout the procedure, which was unremarkable, as was the immediate recovery period. The femoral catheter was kept in situ with 0.2% ropivacaine infused at 6 ml/hour. Transdermal buprenorphine 5 μg/hour was initiated one hour following the procedure.
The femoral nerve catheter infusion was reduced the following day with a view to removal. Increasing pain resulted in the use of oxycodone 12.5 mg and sublingual buprenorphine 1 mg (5 x 200 μg) in divided doses over 10 hours. The patient was found 48 hours post procedure with a GCS of 12, respiratory rate of 12 /minute and an oxygen saturation of 88% on room air. The last buprenorphine dose had been administered six hours earlier. Naloxone was not given due to concerns by the treating clinician regarding development of pulmonary oedema. The buprenorphine patch was removed, further opioid analgesics withheld, and the patient treated with low-flow oxygen and monitored. Her GCS slowly improved to 15 with improved respiratory function and oxygen saturations of 94% on room air. A concurrent mild hyponatraemia had developed over the previous 24 hours (125 mmol/l). It was thought that this could be a possible metabolic contributor to her slightly depressed neurological state. However, her neurological and respiratory function improved despite persistence of the mild hyponatraemia. She made a good recovery, and was transferred to a rehabilitation unit five days later for ongoing care.
Case 4
An 82-year-old man with longstanding rheumatoid arthritis and chronic obstructive pulmonary disease underwent an elective arthroplasty of the metacarpophalangeal and interphalangeal joints of his right hand. A supraclavicular block utilising 10 ml of 0.75% ropivacaine and 10 ml of 2% lignocaine was performed. A median nerve block utilising 5 ml of 0.75% ropivacaine was performed by the surgeons. A target-controlled propofol infusion was administered to provide general anaesthesia throughout the case. Midazolam 2 mg was given at induction. His four and a half hour procedure was uneventful and he was alert and haemodynamically stable with normal observations in the PACU.
Three hours after his procedure he developed significant breakthrough pain which was managed with 1.4 mg (7 x 200 μg) sublingual buprenorphine in divided doses over the next 11 hours. No other central nervous system (CNS) depressant medication was given. The following morning he had a medical emergency team call for reduced oxygen saturation and depressed conscious state. His arterial blood gas shortly after admission to the high dependency unit revealed pH 7.31, PaCO 2 57 mmHg, PaO 2 84 mmHg and HCO 3 -28 mmol/l. Glucose and electrolytes were normal. His initial respiratory rate on HDU admission was 8 /minute. Naloxone 400 μg in two boluses was given, with improved awareness and improved respiratory rate. It was thought his symptoms were due to hypercarbia resulting from a combination of depressant medication and an exacerbation of his underlying respiratory disease. He improved over the next 24 hours without requiring a naloxone infusion.
Case 5
A 91-year-old male was admitted from an aged care facility for control of worsening symptoms related to congestive cardiac failure. He had a history of ischaemic heart disease. On his second day of admission, he experienced right leg pain related to his longstanding post-herpetic neuralgia. His chronic medications included gabapentin 300 mg daily which was continued during his hospital admission. Sublingual buprenorphine 400 μg was administered followed by oral oxycodone 5 mg 90 minutes later. At that time, he was alert, orientated, had a respiratory rate of 15-20 /minute, and had an oxygen saturation over 94% on 1 litre/minute supplemental oxygen via nasal cannulae. Four and a half hours after buprenorphine administration, our medical emergency team was called for reduced respiratory rate (8-10 /minute), oxygen saturations (91% on 2 litres/minute via nasal cannulae) and a reduced level of consciousness (GCS 10). Naloxone 400 μg was administered intravenously, with a mild improvement in GCS to 11. No other sedative or respiratory depressants had been administered. His arterial blood gas at this time showed pH 7.27, PaCO 2 68 mmHg, HCO 3 -27 mmol/l and PaO 2 115 mmHg. His blood glucose was 8.2 mmol/l. A naloxone infusion was commenced at 200 μg/ hour and this was required for the following nine hours. By then he was alert and orientated with a respiratory rate that had improved to 15-20 /minute. A repeat arterial blood gas showed an improved but compensated respiratory acidosis, with PaCO 2 57 mmHg-likely a reflection of his baseline state and underlying chronic lung disease. Buprenorphine and other opioids were avoided for the remainder of his hospital stay. His cardiac status was optimised and he was discharged from hospital four days later.
Case 6
A 68-year-old female with non-union of a distal humerus fracture sustained several months earlier underwent an elective arthroplasty and redo open reduction and internal fixation of her left humerus. Her initial procedure had taken place four months earlier. In addition to general anaesthesia, an infraclavicular brachial plexus catheter was inserted and 0.2% ropivacaine infusion commenced at 5 ml/hour. She had an unremarkable operative and immediate postoperative recovery period.
In addition to a twice daily dose of pregabalin 75 mg (new medication of which patient received three doses) and oxycodone/naloxone 5 mg/2.5 mg combination, buprenorphine was initiated over the following two days to manage breakthrough pain. On day one after her procedure, buprenorphine 1.4 mg sublingually was administered over the course of the day in divided doses. On day two, buprenorphine 1.6 mg sublingually was administered in divided doses. That evening, a medical emergency team call was initiated for reduced conscious state (GCS 8) and respiratory depression. She was noted to have a reduced respiratory effort with a rate of 10/minute. Her PaCO 2 was 70 mmHg, pH 7.25, HCO 3 -30 mmol/l and PaO 2 140 mmHg. Blood glucose and serum electrolytes were normal. Naloxone 2.2 mg was administered in divided doses, with improvement in her GCS to 12. She was admitted to ICU where she received a naloxone infusion for the next seven hours. She made a gradual recovery over the next 11 hours at which time she was awake and alert, and respiratory rate had increased to 14-20 /minute. She was discharged to the ward and had an otherwise unremarkable recovery, being discharged home a few days later. Table 1 provides a summary of patient characteristics and buprenorphine-related events.
Discussion
We found six cases of buprenorphine-related respiratory or neurological depression over a two-year period. All six cases demonstrate buprenorphine's potential to cause or contribute to serious morbidity and mortality. While this number is small, it is alarming, given that many clinicians appear to hold the view that buprenorphine is safe in all patients due to its purported ceiling effect on respiratory depression. As such, even one case of buprenorphinerelated respiratory depression should be of concern, and a case series of six should prompt further investigation and a possible re-evaluation about its safety in higher risk patients. It is clearly evident that buprenorphine's 'ceiling effect' on respiratory depression should not be interpreted as 'no effect' 3,5,6 .
Buprenorphine's apparent ceiling effect may not prevent clinically significant respiratory depression from occurring, particularly in the elderly patient who may have disease or age-related reduced physiological reserve. The physiological effect of buprenorphine on respiratory function was quantified by Dahan et al, who showed in healthy young volunteers that minute ventilation was reduced in a dosedependent manner up to 3 μg/kg IV, after which the effects levelled off at approximately 50% that of baseline 6 . This Emergency if unplanned admission, # Buprenorphine administration-dose and route, ³ eGFR (estimated glomerular filtration rate in ml/min), * Time interval between buprenorphine administration and onset of clinically significant symptom. Time from last dose of buprenorphine if more than one dose given, Ø Medication with respiratory or neurological depressant activity other than buprenorphine. Administered in time interval relevant to event, ¥ Reduction in Glasgow Coma Scale score from baseline, or reported clinical decrease in conscious state, $ As evidenced by reduced respiratory rate or significantly elevated PaCO 2 , AE Naloxone administered as antidote for opiate toxicity, either as bolus and/or continuous infusion, ¤ Time from clinically significant symptoms to return to baseline, § Some improvement in GCS but not to baseline. Clinical deterioration with aspiration pneumonia. EVAR, endovascular aortic repair; TKR, total knee replacement; ORIF, open reduction and internal fixation; MCP, metacarpophalangeal; IP, interphalangeal; CCF, congestive cardiac failure; sl, sublingual; IV, intravenous; sc, subcutaneous; td, transdermal.
was in contrast with fentanyl which caused dose-dependent respiratory depression culminating in apnoea at higher doses 6 . Susceptible elderly patients may demonstrate clinical manifestations when buprenorphine-induced reductions in minute ventilation of up to 50% occur in addition to already compromised physiological reserve. In other words, in patients with reduced respiratory reserve, buprenorphine may cause significant respiratory depression with the potential to produce harm. Of note, all our patients had reduced respiratory reserve due to their age, premorbid condition, or the co-administration of other respiratory or CNS depressants.
The possibility of respiratory depression even at low doses has been highlighted by some authors, and documented cases of such adverse effects of buprenorphine in combination with other CNS depressant medications have been published [7] [8] [9] [10] [11] [12] . An early trial comparing sublingual buprenorphine with ketobemidone (another synthetic opioid) in postoperative pain was abandoned early when lateonset respiratory depression, not responding to naloxone, occurred in three patients 8 . A number of recent studies in the paediatric literature have also highlighted serious toxicity including respiratory depression after accidental buprenorphine overdose 13, 14 . These have followed initial reports suggesting buprenorphine did not produce significant toxicity in children due to the ceiling effect on respiratory depression 15 .
The respiratory depressant effect of opioids is typically measured experimentally using a method to maintain a fixed end-tidal carbon dioxide 5, 6 . This method highlights the respiratory depressive effect of buprenorphine, independent of rising PaCO 2 , on ventilatory drive and conscious state 5 . Clinically, PaCO 2 increases with increasing respiratory depression. However, in the clinical setting some patients may not respond effectively to rising PaCO 2 . The resultant hypercapnia may eventually depress conscious state and airway control leading to further respiratory and CNS depression 16 . The respiratory and neurological depression observed in the six cases of our series are likely to be due both to the direct respiratory depressive effect of buprenorphine and the CO 2 narcosis (measured PaCO 2 ranging from 57 to 106 mmHg).
Clinically significant respiratory depression associated with buprenorphine evident in this case series appears to be multifactorial. The depressant effect of buprenorphine may be potentiated by increasing age, diminishing acute pain, patient fatigue due to illness and sleep deprivation, and concurrent medical conditions. Apart from known clinical risk factors, genetic factors and drug interactions may play a role in the development of greater than expected respiratory depression 2 . P-glycoprotein (P-gp), a transporter for several opioids, plays a protective role by allowing the efflux of norbuprenorphine at the blood-brain barrier 17 . Norbuprenorphine, the main metabolite of buprenorphine, has 10 times the respiratory depressant effect compared with buprenorphine 1 . Reduced function of P-gp in the elderly may result in accumulation of norbuprenorphine in the brain compartment 17 . There may also be reduced expression of the glycoprotein due to a polymorphism of the gene ABCB1, the gene encoding for P-gp, or a drug-induced interaction 2, [17] [18] [19] .
The high doses of naloxone needed as an antidote to buprenorphine-related respiratory depression were apparent in five of our cases. Two of the patients received a naloxone bolus of between 1 and 2 mg and one patient received a 2.2 mg bolus of naloxone. Underdosing of naloxone, apparent in these cases, may be partly attributed to theoretical concerns by some regarding the adverse effects of large doses of naloxone, such as the development of pulmonary oedema [20] [21] [22] . Buprenorphine's high affinity and slow dissociation from opioid receptors makes it relatively resistant to attempts at reversal with naloxone 18 . Re-narcotisation is likely after a single naloxone dose due to the slow dissociation of buprenorphine from receptors and the fast elimination kinetics of naloxone 20, 22, 23 . This is in contrast with other opioids such as fentanyl, for example, which shows full reversal of respiratory depression with a short infusion of low doses of naloxone 7 . Relatively large doses of naloxone (2-3 mg bolus) followed by a continuous infusion of up to 4 mg/hour are necessary to attain full reversal of respiratory depression with clinically relevant doses of 200-400 μg buprenorphine 7, 23 .
Our case series highlights various potential issues regarding the monitoring of elderly hospitalised opioid-naïve patients receiving buprenorphine. Traditionally, in patients receiving opioids, respiratory rate and oxygen saturation have been employed as surrogate measures of respiratory depression. PaCO 2 measurements represent a sensitive clinical marker of respiratory depression. When measured in this case series, CNS depression occurred at a range of PaCO 2 from 57 to 106 mmHg. Reduced conscious state (increasing sedation) is an additional consideration when monitoring for respiratory depression in patients receiving buprenorphine.
As with all case series, the small number of patients, the uncontrolled environment and nature of interventions make it difficult to establish firm associations. The retrospective nature also introduces limitations in making inferences. However the central role of buprenorphine in these cases is apparent. Four of the cases involved temporally related administration of oxycodone or codeine. However naloxone has been shown to readily reverse any such effects at the doses prescribed in the cases presented 24 . Nevertheless, the combination of the use of buprenorphine for acute pain in elderly opioid-naïve patients with limited respiratory reserve or the concurrent administration of other potential CNSdepressant medications appeared to be a consistent feature across all six patients.
In conclusion, this case series highlights the potential complications and management issues with buprenorphine use in elderly, opioid-naïve hospitalised patients. Any perception that an apparent ceiling of respiratory depression precludes significant respiratory adverse events from occurring needs to be corrected. Consideration should be given to the avoidance of buprenorphine use in the elderly even in the absence of other risk factors. If prescribed, a 'start low go slow' approach with a low initial dose and careful titration is advised. We recommend additional caution when considering buprenorphine for acute pain management in this group of patients together with additional monitoring and education about the potential adverse effects.
